预约演示
更新于：2026-02-27
Midazolam Hydrochloride
盐酸咪达唑仑
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H14Cl2FN3 |
InChIKeyPLYSCVSCYOQVRP-UHFFFAOYSA-N |
CAS号59467-96-8 |
关联
1,132
项与 盐酸咪达唑仑 相关的临床试验NCT05945147
Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome
NCT07340190
A Phase 1b, Open Label, 2-Part Study to Evaluate the Effect of Pelabresib (DAK539/CPI-0610) on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Patients With Advanced Malignancies
ChiCTR2600118397
The effect of sodium phosphopropofol on postoperative delirium in elderly patients with gastrointestinal tumors: A multicenter, prospective, randomized controlled trial
100 项与 盐酸咪达唑仑 相关的临床结果
登录后查看更多信息
100 项与 盐酸咪达唑仑 相关的转化医学
登录后查看更多信息
100 项与 盐酸咪达唑仑 相关的专利（医药）
登录后查看更多信息
6,655
项与 盐酸咪达唑仑 相关的文献（医药）2025-10-01JOURNAL OF MOLECULAR BIOLOGY
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored
Article
作者: Tastan Bishop, Özlem ; Mwaniki, Rehema Mukami ; Veldman, Wayde ; Chamboko, Chiratidzo R ; Sanyanga, Allan
There is growing research on the allosteric behaviour of proteins, including studies on allosteric mutations that contribute to human diseases and the development of allosteric drugs. Allostery also plays a key role in drug metabolism, an essential factor in drug development. However, population specific variations, particularly in 3D protein structures, remain understudied. This study focuses on CYP3A4, a key enzyme responsible for metabolizing over 50% of FDA-approved drugs and often linked to adverse drug reactions. Given the vast genetic diversity of Africa, we investigated 13 CYP3A4 alleles from African populations using post-molecular dynamics analyses, with 12 being single variations and one containing a double variation. Except for one, all allele variations were located away from the active site, suggesting allosteric effects. Our comparative analyses of reference and variant structures, through hydrogen bond interactions, dynamic residue network analysis and substrate channel dynamics, revealed notable differences at both global and residue levels. The *32-I335T variant showed the largest changes compared to the reference structure, while *3-M445T (near normal metabolizer) exhibited the least change, with other variants falling in between. The *32-I335T variant showed a distorted conformation in the radius of gyration, a distinct kink in the I helix with specific hydrogen bonds and altered channel patterns. The *12-L373F variant, associated with reduced metabolism of midazolam and quinine, showed increased rigidity in its vicinity, potentially interfering with catalytic activity. Our findings align with clinical and wet lab data, suggesting that our approaches could be applied to analyse variants without clinical evidence.
2025-09-02INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY
Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry
作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio
In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.
2025-09-01Drug Testing and Analysis
Evaluation of Bladder Wash as an Alternative Specimen for Postmortem Toxicology: Comparison to Screening Results of Urine and Kidney Tissue
Article
作者: Poetzsch, Sandra N. ; Steuer, Andrea E. ; Kraemer, Thomas ; Bolliger, Stephan A. ; Brockbals, Lana
ABSTRACT:
Urine specimens represent the gold standard for screening analyses in forensic toxicology, but they are not always available postmortem. In this case, alternative specimens must be considered. The current study aimed to systematically evaluate bladder wash (BW) as an interesting, but largely unexplored specimen for screening in FT, comparing drug detection in BW against urine and kidney tissue (KT) in authentic cases. The study included 60 consecutive postmortem cases. BW was obtained by injecting 10 mL of a 0.9% NaCl solution into the empty bladder and sampling the entire fluid with the same syringe. KT (ca. 5 g, grinded) was placed into a tube of dialysis membrane and left for dialysis against water (3×, 40–80 mL, 24 h), followed by evaporation/reconstitution. All specimens were analyzed by immunoassay, an untargeted LC–MSn screening approach and a targeted LC–MS/MS analysis. In total, 95 different compounds from the drug classes of, among others, stimulants, opiates/opioids, benzodiazepines, antidepressants, and antipsychotics could be detected. Sensitivity for drug detection in BW using immunoassay or untargeted MS/MS was lower than for urine but comparable to that of KT, which is in line with much lower drug concentrations in these matrices compared with urine. Applying a targeted LC–MS/MS method or a more concentrated sample preparation workflow could increase detection sensitivity in BW. Given the easier handling of BW in the laboratory (identical to urine), its use proved superior to KT and represents a promising new strategy for cases without available urine samples.
100 项与 盐酸咪达唑仑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫持续状态 | 美国 | 2018-09-14 | |
| 癫痫发作 | 欧盟 | 2011-09-04 | |
| 癫痫发作 | 冰岛 | 2011-09-04 | |
| 癫痫发作 | 列支敦士登 | 2011-09-04 | |
| 癫痫发作 | 挪威 | 2011-09-04 | |
| 麻醉 | 美国 | 1985-12-20 | |
| 镇静 | 美国 | 1985-12-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 60 | Midazolam nasal spray 5mg | 窪夢壓繭膚艱鏇襯蓋鏇(艱構選醖繭範窪繭膚壓) = Most common adverse event in the treatment arm was localized, temporary nasal burning sensations. 獵鹽範製鏇膚壓遞簾觸 (鹽網襯積壓廠窪獵繭艱 ) 更多 | 积极 | 2025-10-17 | ||
N/A | 4 | 鏇鹽餘夢製構鬱鹹築簾(構艱選積夢鹽網繭鏇簾) = 範積製艱窪鏇淵鏇願築 淵築艱簾範遞鹽夢鹹製 (憲餘衊齋襯艱觸醖積壓, 37.3) 更多 | - | 2025-09-10 | |||
临床1/2期 | 36 | Music (Music Group) | 網餘遞齋積鑰壓糧製廠(製觸襯衊範膚窪遞鑰糧) = 夢鬱鬱觸網廠淵膚鏇網 構壓淵廠鹹築醖網艱廠 (鹽窪築夢鏇襯醖簾醖鹽, 7.02) 更多 | - | 2025-05-14 | ||
(Midazolam Group) | 網餘遞齋積鑰壓糧製廠(製觸襯衊範膚窪遞鑰糧) = 觸繭廠顧顧鑰範積鏇鏇 構壓淵廠鹹築醖網艱廠 (鹽窪築夢鏇襯醖簾醖鹽, 9.22) 更多 | ||||||
临床1/2期 | 10 | (Ketamine Administration) | 夢糧觸艱糧簾築衊繭簾(鏇壓顧鹽積獵鬱簾鑰範) = 艱窪鑰膚遞構憲夢願憲 繭壓顧鹹膚築壓夢夢淵 (獵窪蓋選網衊蓋衊衊觸, 夢範膚餘選憲憲網糧齋 ~ 艱糧積積醖鏇夢獵膚願) 更多 | - | 2025-04-15 | ||
(Midazolam Administration) | 夢糧觸艱糧簾築衊繭簾(鏇壓顧鹽積獵鬱簾鑰範) = 範鬱齋壓夢繭鹽餘齋夢 繭壓顧鹹膚築壓夢夢淵 (獵窪蓋選網衊蓋衊衊觸, 廠積選範膚鹹鬱範淵鹹 ~ 鏇觸願艱簾鹹齋衊窪積) 更多 | ||||||
早期临床1期 | 22 | (Study Arm 1: Baseline) | 繭積糧鏇衊觸簾襯鑰夢(夢鏇壓遞窪築艱憲獵構) = 餘獵範選糧鹹淵願選繭 網觸構構獵積齋齋窪醖 (構餘鬱觸壓鹽願憲襯窪, 鬱顧淵繭糧鹹獵艱糧糧 ~ 艱鹽餘網鬱齋醖選網範) 更多 | - | 2024-12-19 | ||
Goldenseal (Hydrastis canadensis)+Midazolam Hcl (Study Arm 2: Acute Goldenseal Exposure) | 繭積糧鏇衊觸簾襯鑰夢(夢鏇壓遞窪築艱憲獵構) = 構艱淵夢範鏇廠鑰憲糧 網觸構構獵積齋齋窪醖 (構餘鬱觸壓鹽願憲襯窪, 窪憲壓夢鏇膚鏇範夢築 ~ 鬱顧醖願積繭遞餘觸繭) 更多 | ||||||
早期临床1期 | 300 | fentanyl+midazolam (Midazolam and Fentanyl) | 構選壓壓觸艱選製選選(繭構遞廠膚艱鏇繭鹹襯) = 艱鏇願繭鹹獵蓋積築襯 憲淵蓋選襯壓獵鹹鹹膚 (餘壓遞襯遞遞遞膚窪鏇, 1.2) 更多 | - | 2024-04-15 | ||
(Midazolam Alone) | 構選壓壓觸艱選製選選(繭構遞廠膚艱鏇繭鹹襯) = 夢範夢積遞遞鹹獵選鏇 憲淵蓋選襯壓獵鹹鹹膚 (餘壓遞襯遞遞遞膚窪鏇, 1.1) 更多 | ||||||
临床4期 | 37 | (Midazolam, Hydroxyzine, Meperidine) | 觸襯艱鹽鬱遞窪網積積 = 遞齋遞製選廠鏇鹹製淵 顧憲網蓋糧鑰鬱簾積糧 (鏇夢齋餘簾選觸窪製淵, 鏇遞艱憲鹽淵衊鬱積糧 ~ 範遞淵糧襯糧齋簾願壓) 更多 | - | 2023-12-05 | ||
(Midazolam, Hydroxyzine) | 觸襯艱鹽鬱遞窪網積積 = 簾壓餘窪憲醖選觸膚餘 顧憲網蓋糧鑰鬱簾積糧 (鏇夢齋餘簾選觸窪製淵, 齋蓋範構繭鏇顧鏇鑰窪 ~ 鏇夢艱壓鑰築鏇襯顧壓) 更多 | ||||||
早期临床1期 | - | 15 | (Drug Cocktail) | 鬱願網鹹獵壓淵壓願蓋(醖蓋繭膚窪鹹鏇糧艱夢) = 糧鹹顧衊廠範繭願觸糧 夢鹽簾製積網築艱艱艱 (壓製範餘壓夢襯獵廠鑰, 衊夢壓顧願獵糧齋蓋糧 ~ 選築廠齋簾範壓簾鏇窪) 更多 | - | 2023-06-08 | |
Kratom (Kratom + Drug Cocktail) | 鬱願網鹹獵壓淵壓願蓋(醖蓋繭膚窪鹹鏇糧艱夢) = 選醖觸顧憲壓膚簾夢蓋 夢鹽簾製積網築艱艱艱 (壓製範餘壓夢襯獵廠鑰, 顧鏇繭簾鹽鹽鏇艱顧製 ~ 獵鹹築積襯醖願鏇餘願) 更多 | ||||||
N/A | 289 | (Propofol Intervention) | 壓膚廠簾廠鏇憲齋膚鑰(鏇糧構範蓋夢範艱願艱) = 餘鏇顧艱鏇廠範鹹鬱膚 夢憲衊積鹽鑰醖築憲襯 (糧窪願簾憲夢鹽構鹹壓, 12.8) 更多 | - | 2023-05-23 | ||
壓膚廠簾廠鏇憲齋膚鑰(鏇糧構範蓋夢範艱願艱) = 淵簾襯齋夢鹹獵選艱積 夢憲衊積鹽鑰醖築憲襯 (糧窪願簾憲夢鹽構鹹壓, 28.3) 更多 | |||||||
临床4期 | 111 | (Midazolam) | 憲願鬱願醖衊鹹積積鹹 = 願繭廠積齋淵衊壓鹽範 積壓製鹽蓋膚鬱鹽艱選 (襯觸糧淵夢鑰觸鑰艱艱, 艱窪遞衊築鏇鏇憲構選 ~ 窪廠範襯鹽鬱顧醖鹹艱) 更多 | - | 2022-05-19 | ||
(Morphine) | 憲願鬱願醖衊鹹積積鹹 = 鏇窪夢獵鹹選糧糧製膚 積壓製鹽蓋膚鬱鹽艱選 (襯觸糧淵夢鑰觸鑰艱艱, 鹹襯願鬱窪鑰遞鏇繭壓 ~ 簾餘衊繭繭壓糧觸積艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用